CS
HZNP

Credit Suisse’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Credit Suisse’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-327,898
Closed -$37.9M – 3203
2023
Q3 		$37.9M Buy
327,898
+14,898
+5% +$1.6M 0.04% 453
2023
Q2 		$32.2M Sell
313,000
-61,293
-16% -$6.47M 0.03% 527
2023
Q1 		$40.9M Buy
374,293
+11,707
+3% +$1.29M 0.04% 453
2022
Q4 		$41.3M Buy
362,586
+66,068
+22% +$5.49M 0.04% 453
2022
Q3 		$18.4M Sell
296,518
-8,406
-3% -$587K 0.02% 683
2022
Q2 		$24.3M Sell
304,924
-106,635
-26% -$10.1M 0.03% 627
2022
Q1 		$43.3M Buy
411,559
+4,878
+1% +$475K 0.04% 500
2021
Q4 		$43.8M Buy
406,681
+16,630
+4% +$1.81M 0.02% 706
2021
Q3 		$42.7M Buy
+390,051
New +$40.5M 0.02% 701
2021
Q2 		– Sell
-239,297
Closed -$22M – 847
2021
Q1 		$22M Sell
239,297
-4,389
-2% -$370K 0.01% 1111
2020
Q4 		$17.8M Buy
243,686
+66,844
+38% +$4.97M 0.01% 1235
2020
Q3 		$13.7M Sell
176,842
-45,763
-21% -$3.15M 0.01% 1200
2020
Q2 		$12.4M Sell
222,605
-102,498
-32% -$4.39M 0.01% 1195
2020
Q1 		$9.63M Buy
325,103
+142,454
+78% +$4.82M 0.01% 1195
2019
Q4 		$6.61M Buy
182,649
+35,171
+24% +$1.08M ﹤0.01% 1688
2019
Q3 		$4.02M Sell
147,478
-104,458
-41% -$2.7M ﹤0.01% 1937
2019
Q2 		$6.06M Buy
251,936
+76,926
+44% +$1.95M 0.01% 1621
2019
Q1 		$4.63M Sell
175,010
-139,650
-44% -$3.31M ﹤0.01% 1766
2018
Q4 		$6.15M Buy
314,660
+124,285
+65% +$2.44M 0.01% 1449
2018
Q3 		$3.73M Sell
190,375
-18,288
-9% -$348K ﹤0.01% 1898
2018
Q2 		$3.46M Buy
208,663
+6,039
+3% +$92.1K ﹤0.01% 2020
2018
Q1 		$2.88M Buy
202,624
+36,712
+22% +$542K ﹤0.01% 2132
2017
Q4 		$2.42M Sell
165,912
-65,394
-28% -$918K ﹤0.01% 2289
2017
Q3 		$2.93M Buy
231,306
+37,030
+19% +$471K ﹤0.01% 2219
2017
Q2 		$2.31M Buy
194,276
+18,260
+10% +$227K ﹤0.01% 2142
2017
Q1 		$2.6M Sell
176,016
-48,602
-22% -$787K ﹤0.01% 2156
2016
Q4 		$3.63M Sell
224,618
-53,999
-19% -$979K ﹤0.01% 1904
2016
Q3 		$5.05M Buy
278,617
+18,515
+7% +$362K ﹤0.01% 1647
2016
Q2 		$4.28M Buy
260,102
+122,744
+89% +$1.99M ﹤0.01% 1745
2016
Q1 		$2.28M Buy
137,358
+15,489
+13% +$271K ﹤0.01% 2102
2015
Q4 		$2.64M Buy
121,869
+13,680
+13% +$266K ﹤0.01% 2082
2015
Q3 		$2.14M Sell
108,189
-200,332
-65% -$6.33M ﹤0.01% 2209
2015
Q2 		$10.7M Buy
308,521
+199,945
+184% +$6.1M 0.01% 1202
2015
Q1 		$2.82M Sell
108,576
-111,030
-51% -$2.04M ﹤0.01% 2105
2014
Q4 		$2.83M Buy
219,606
+171,759
+359% +$2.15M ﹤0.01% 2238
2014
Q3 		$587K Sell
47,847
-4,064
-8% -$47.2K ﹤0.01% 3518
2014
Q2 		$822K Sell
51,911
-54,044
-51% -$771K ﹤0.01% 3465
2014
Q1 		$1.6M Buy
105,955
+31,579
+42% +$357K ﹤0.01% 2694
2013
Q4 		$567K Buy
+74,376
New +$401K ﹤0.01% 3691
2013
Q3 		– Sell
-19,548
Closed -$48K – 4439
2013
Q2 		$48K Buy
+19,548
New +$46.9K ﹤0.01% 4102

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's HZNP Position: Q4 2023 in Review

Credit Suisse sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 327,898 shares — an estimated $37.9M sold.

Credit Suisse first reported a position in HZNP in Q2 2013 and held it in 40 quarters. The position peaked at $43.8M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Credit Suisse reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 327,898 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $37.9M.
  • Credit Suisse first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 40 quarters.
  • Credit Suisse's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $43.8M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.